交易 uniQure N.V. - QURE 差价合约

交易条件

• 类型该金融市场可进行差价合约交易。了解更多:差价合约: 差价合约
• 点差: 0.14
• 长仓隔夜仓息调整长仓隔夜仓息调整保证金。您的投资$1,000.00隔夜仓息来自头寸全值的费用-0.022262 %(-$0.45)使用杠杆的交易规模（大约值）$2,000.00来自杠杆的资金 - 美元（大约值）$1,000.00前往平台: -0.02226%
• 短仓隔夜仓息调整短仓隔夜仓息调整保证金。您的投资$1,000.00隔夜仓息来自头寸全值的费用0.00004 %($0.00)使用杠杆的交易规模（大约值）$2,000.00来自杠杆的资金 - 美元（大约值）$1,000.00前往平台: 0.00004%
• 隔夜调整仓息时间: 21:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价保证止损 (GSL) 费用仅在 GSL 被触发时收取。更多详情请参阅我们网站的“服务费用”页面。: 1%

• 保证金。您的投资: $1,000.00
• 隔夜仓息来自头寸全值的费用: -0.022262 %
  (-$0.45)

• 保证金。您的投资: $1,000.00
• 隔夜仓息来自头寸全值的费用: 0.00004 %
  ($0.00)

主要统计数据

• 前收盘价: 23.31
• 开仓: 23.21
• 1 年变化: 0.83%
• 日区间: 22.78 - 23.47

交易 uniQure N.V. - QURE

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington''s disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer''s disease; and AMT-210 that is in preclinical trial to treat Parkinson''s disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.